Aclaris Therapeutics, Inc. ACRS

Updated: 10 Aug 2026

NASDAQ | Biotech | Biotechnology / drug development

No signal published yet

We already track Aclaris Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Aclaris Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology / drug development
We're already tracking Aclaris Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On August 6, 2026, Aclaris Therapeutics reported its second quarter 2026 financial results with a net loss of $21.5 million and $170.6 million in cash, cash equivalents, and marketable securities. Subsequent equity sales generated $40.2 million in gross proceeds, extending the company's projected cash runway through 2028. In addition, the U.S. FDA granted Fast Track designation for modzatinib (ATI-2138) for the treatment of moderate to severe lichen planus.

What Firelda Watch includes for Aclaris Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Aclaris Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow Aclaris Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Aclaris Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics — follow and we'll monitor it
Follow Aclaris Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.